Related Experiment Video
Updated: May 4, 2026

Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets
Published on: February 23, 2024
The impact of cost-sharing schemes on drug compliance in Italy: evidence based on quantile regression
Vincenzo Atella1, Joanna Aleksandra Kopinska
1Department of Economics and Finance, University of Rome Tor Vergata, CHP PCOR Stanford University, Via Columbia, 2, 00133, Rome, Italy, atella@uniroma2.it.
Objectives:
In this article we investigate the causal effect of cost-sharing schemes on compliance with statins in a quantile regression framework.
Methods:
We use the health search CSD-LPD data, a longitudinal observational dataset containing computer-based patient records collected by Italian general practitioners. We exploit a series of natural experiments referring to several introductions of co-payment schemes in some of the Italian regions between 2000 and 2009. We adopt an extended difference-in-differences approach to provide quantile estimates of the impact of co-payments on compliance.
Results:
We find that (i) introduction of co-payments hurts residents of regions with worse quality and provision of health care; (ii) within these regions, co-payments were particularly harmful for high compliers; (iii) gender, clinical history and geographic residence are important determinants of compliance among poor compliers; (iv) compliance decreases with the potency and dosage of statins, particularly for poor compliers.
Conclusions:
In the presence of inefficient health-care provision, co-payments are harmful for drug compliance, and this is especially true for patients who are originally good compliers.
More Related Videos
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Quantitative Aspects of Drug-Receptor Interaction
Drug Control Governance: Regulatory Bodies and Their Impact
Dosage Regimens: Partial Pharmacokinetic Parameters
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Analysis of Population Pharmacokinetic Data

